At present, my country's biopharmaceutical industry continues to unleash its innovative vitality and is accelerating towards a new stage of innovation-driven, achievement transformation and international development. In recent years, Bank of China has continued to leverage its global advantages and comprehensive characteristics, focusing on the entire chain and full life cycle financial needs of the biopharmaceutical industry, continuously enriching the innovative product matrix, iteratively upgrading financial services, resonating with the industry, and growing with enterprises.
Based on the background of the construction of the national drug traceability supervision system, and in-depth exploration of the credit value of the "drug traceability code", Bank of China recently launched an innovative financing service plan, relying on the "drug traceability code" to successfully implement pharmaceutical "on-code" factoring business for a pharmaceutical distribution company in Sichuan, transforming the true "information flow" of drugs from production, warehousing to circulation and distribution into a financing "pass" for pharmaceutical companies.
Use "code" as the medium. Bank of China deeply integrates drug traceability codes and supply chain finance, using the entire drug chain circulation trajectory as a credible basis for trade background risk control verification, effectively promoting the transformation of regulatory data into credit assets.
Increase credit by "tracing back". On the basis of cross-verifying the authenticity of logistics, information flow, and capital flow backgrounds, Bank of China provides "buyout" non-recourse factoring financing services to pharmaceutical companies, helping pharmaceutical companies to quickly verify accounts receivable and realize cash in advance.
The implementation of this business truly achieves "allowing more data to run away and pharmaceutical companies to wait less", effectively clearing up financing bottlenecks for enterprises, easing the financial pressure on the upstream and downstream of the pharmaceutical industry chain, and helping to build a closed-loop financial ecosystem for the pharmaceutical industry.
Build a "1+4" service matrix to accompany the growth of the entire chain
The implementation of the pharmaceutical "Mashang" factoring business is a vivid epitome of Bank of China's service to the biomedical industry. In recent years, Bank of China has continued to focus on the core needs of enterprises in the biopharmaceutical industry chain. In May this year, it released the "Action Plan to Support the Innovation and Development of the Whole Chain of Biopharmaceuticals" and built a "1+4" product service system: a "through-type cultivation plan" to provide full-cycle accompaniment of equity loan synergy, and "Pipeline R&D Loans", "BD Loans", "Concentrated Procurement Loans" and "New Premium Catalog Loans" to accurately match the financing needs of enterprises at each stage, and promote financial resources to more accurately and efficiently empower the development of the biopharmaceutical industry.
Investment and loan integration empowers the growth of R&D enterprises
In view of the long research and development cycle and high capital demand of innovative drugs, Bank of China has created a through-training model of "equity-loan linkage" to coordinate the group's equity and debt resources to provide continuous, full-cycle financial escort for innovative drug companies.
In the early R&D stage of a cell and gene therapy company in Shenzhen, Bank of China coordinated the direct equity investment within the group to complete the equity investment. After the company achieved core technology breakthroughs, it quickly followed up with credit support and provided integrated financial services to escort the company steadily from the start-up stage to the growth stage.
Breaking through the traditional model to accurately support pipeline research and development
In response to the financing pain points of "high R&D investment, light assets, and lack of collateral" for start-up enterprises, Bank of China innovatively launched the "Pipeline R&D Loan", which breaks out of the traditional evaluation framework and conducts comprehensive evaluations from the core team, R&D data, investment evaluation, market prospects and other dimensions.
In Suzhou, when a small molecule targeted drug company faced financial constraints in the clinical stage, the Bank of China comprehensively evaluated the company's R&D pipeline, clinical progress, and capital operation arrangements, and relied on the "Pipeline R&D Loan" to approve special credit for the company to help the company smoothly carry out Phase II and Phase III clinical trials and achieve clinical breakthroughs.
Seize BD market opportunities to help pharmaceutical companies innovate overseas
Currently, my country’s innovative drug external technology licensing (License-out) transaction scale ranks among the top in the world. In response to the industry pain point of time mismatch in staged payments in overseas business development (BD) transactions, Bank of China innovatively launched "BD Loan" to provide transitional liquidity support based on the forward income of the authorization agreement.
In Sichuan, a leading ADC innovative drug company has completed overseas BD authorization for its core pipeline and has locked in forward commercialization-related profits. However, due to the arrangement of transaction payment nodes, there is a time mismatch in capital inflows. Bank of China comprehensively evaluates the company's patent reserves, clinical progress, licensing transaction terms and future cash flow, and provides companies with long-term, large-amount "BD loans" to optimize their overall capital structure and help China's original new drugs enter the international market.
Broaden application scenarios and focus on the transformation of scientific and technological achievements
Innovative pharmaceutical products move from research and development results to the broad market, relying on the in-depth integration of policy guidance, market application and industrial chain coordination. Bank of China explores the transformation of industrial policies into financial service basis based on policy scenarios such as centralized procurement organized by the state and the catalog of new and high-quality pharmaceuticals and equipment.
Bank of China has innovatively launched "Concentrated Purchasing Loan" and "New and Excellent Catalog Loan". Based on the national centralized purchasing bid winning orders and the pharmaceutical "New and Excellent Product Catalog" issued by various regions as important credit basis, it provides enterprises with special financial support for the fulfillment of centralized procurement contracts and the expansion of new and excellent products. It effectively alleviates the capital turnover pressure in the commercialization process of enterprises and helps the industry achieve the leap from "innovative research and development" to "market leadership".
